Exelixis (EXEL) director Heyman received 8,367 shares
Insider transactions reported
Tomas J. Heyman (director at Exelixis Inc., EXEL) reported that they received 8,367 shares on May 27, 2026. After these transactions the filing shows 50,649 shares held directly.
- Reporting person
- Heyman Tomas J.
| Date | Type | Security | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|
| May 27, 2026 | Grant or award (A) | Common Stock1, 2 | +8,367 | - | - | 50,649 direct |
Holdings before and after
- Common Stock: 42,282 to 50,649 direct
Footnotes from the filing
- 1. Represents restricted stock units ( RSUs ) granted to the Reporting Person on the Transaction Date pursuant to the Exelixis, Inc. 2017 Equity Incentive Plan. Each RSU is the economic equivalent of one share of Exelixis, Inc. common stock ( Common Stock ). The RSUs will vest as to 100% of the shares subject to the RSU award on May 27, 2027, subject to the Reporting Person's continuous service through that date.
- 2. Includes 17,455 shares of Common Stock that will be issued to the Reporting Person upon vesting of RSUs.
Transaction codes in this filing
- Grant or award:
- Code A marks a grant or award from the company under an exempt employee or director plan. Usually nothing is paid for it.
FAQ
What did Heyman report in this EXEL Form 4?
Tomas J. Heyman (director at Exelixis Inc., EXEL) reported that they received 8,367 shares on May 27, 2026. After these transactions the filing shows 50,649 shares held directly.
How many EXEL shares does Heyman hold after this filing?
The filing shows 50,649 shares held directly after the reported transactions. Form 4 reports only the positions it lists, so this may not be every holding.
What does transaction code A mean on an SEC Form 4?
Code A marks a grant or award from the company under an exempt employee or director plan. Usually nothing is paid for it.
Historical context for EXEL
Across the 22 sessions after earlier EXEL headlines, the stock closed higher 13 times and lower 9 times, with a median move of 2.4% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | EXEL | SPY |
|---|---|---|---|
| May 28, 2026 | Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in June | +2.8% | +0.6% |
| May 22, 2026 | Exelixis Announces Presentations at ASCO 2026 Highlighting Ongoing Studies in Diverse Tumor Types | +1.0% | +0.4% |
| May 19, 2026 | Exelixis Announces Clinical Development Collaboration with Merck for Phase 3 STELLAR-316 Pivotal Trial for Patients with Colorectal Cancer | -2.3% | -0.7% |
| May 8, 2026 | Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in May | +4.2% | +0.8% |
| May 6, 2026 | Exelixis Announces First Quarter 2026 Financial Results and Provides Corporate Update | +9.6% | +1.4% |
| Apr 22, 2026 | Exelixis to Release First Quarter 2026 Financial Results on Tuesday, May 5, 2026 | +2.1% | +1.0% |
Earlier insider filings at EXEL
- May 29, 2026Director Smith Julie was granted 8,367 shares, increasing direct ownership by 41% to 28,957 units (SEC Form 4)
- May 29, 2026Director Freire Maria C was granted 8,367 shares, increasing direct ownership by 8% to 109,186 units (SEC Form 4)
- May 29, 2026Director Beckerle Mary C was granted 8,367 shares, increasing direct ownership by 48% to 25,891 units (SEC Form 4)
- May 29, 2026Director Oliver Bob was granted 8,367 shares, increasing direct ownership by 40% to 29,487 units (SEC Form 4)
- May 29, 2026Director Wyszomierski Jack L was granted 8,367 shares, increasing direct ownership by 3% to 288,309 units (SEC Form 4)
Keep researching EXEL
- EXEL insider tradesEvery buy and sale reported by Exelixis Inc. officers, directors and large holders.
- What is Form 4?The SEC filing that reports a change in an insider's holdings, such as a purchase, sale, option exercise or grant, generally within two business days.
- Form 4 explainedForm 4 is the SEC filing that discloses when officers, directors and 10% owners buy or sell company stock, due within 2 business days. Learn every key field and code.
- Insider trading trackerThe latest insider buys and sales across every stock.
- EXEL earnings historyPast Exelixis Inc. earnings releases, newest first.
- EXEL financial statementsRevenue, profit, cash flow and balance sheet from Exelixis Inc.'s SEC filings.
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Listed since
- 2000
Follow EXEL and get a push notification the moment its next story breaks.